Technical Analysis for CRL - Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc., together with its subsidiaries, provides research models and associated services, and outsourced preclinical services to accelerate the drug discovery and development process. It operates in two segments, Research Models and Services (RMS), and Preclinical Services (PCS). The RMS segment is involved in the production and sale of research model strains, principally genetically and microbiologically defined purpose-bred rats and mice for use by researchers. This segment also offers a range of services to assist customers in the drug discovery and development process, which include genetically engineered models and services, insourcing solutions, discovery research services, research animal diagnostic services, endotoxin and microbial detection products and services, and avian vaccine products and services. The PCS segment provides preclinical services, including both in vivo and in vitro studies, supportive laboratory services, and strategic preclinical consulting and program management to support product development. This segment offers services in the areas of bioanalysis, pharmacokinetics, and drug metabolism; toxicology; and pathology services, as well as testing of biologics and devices frequently outsourced by pharmaceutical and biotechnology companies. The company serves pharmaceutical companies, biotechnology companies, government agencies, hospitals, and academic institutions worldwide. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.